Determination of magnesium body concentration

US12391990B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12391990-B2
Application numberUS-202017621996-A
CountryUS
Kind codeB2
Filing dateJun 24, 2020
Priority dateJun 24, 2019
Publication dateAug 19, 2025
Grant dateAug 19, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The presently-disclosed subject matter includes methods for detecting methylation biomarkers in a biological sample from a subject in need of assessment for magnesium deficiency status, methods of diagnosing magnesium deficiency, methods of diagnosing magnesium insufficiency, methods of treating magnesium deficiency, methods of diagnosing magnesium insufficiency, and methods of preventing or reducing a risk of developing a condition linked to magnesium deficiency.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for predicting and treating magnesium deficiency in a subject, said method comprising: a) detecting methylation at CpG sites in DNA obtained from a biological sample from the subject, wherein the subject is in need of assessment for magnesium deficiency status; and b) identifying the subject as being in need of magnesium supplementation when methylation is found at the CpG site: cg00430271 or cg25731074; and c) administering an effective amount of magnesium to the identified subject. 2. The method of claim 1 , and further comprising detecting 5-hydroxymethylcytosine (5-hmC) and 5-methylcytosine (5-mC) methylation in the DNA obtained from the biological sample from the subject and differentiating between 5-hmC and 5-mC methylation in the sample. 3. The method of claim 1 , further comprising detecting 5-hmC and 5-mC methylation, 5-hmC methylation, or 5-mC methylation by performing bisulfite (BS) treatment of the DNA in the biological sample. 4. The method of claim 2 , further comprising differentiating between 5-hmC and 5-mC methylation in the biological sample using a TAB-Seq and TAB-Array protocol. 5. The method of claim 1 , and further comprising determining for the subject a magnesium tolerance test (MTT) score, where an MTT score of greater than or equal to 50% is further indicative of a magnesium deficiency, an MTT score of less than 50% and greater than or equal to 25% is further indicative of a magnesium insufficiency, and an MTT score of less than 25% is further indicative of a magnesium sufficiency. 6. The method of claim 1 , and further comprising identifying the subject as being in need of magnesium supplementation when methylation is found at the CpG sites comprising: cg00430271 and cg25731074. 7. The method of claim 6 , and further comprising administering an effective amount of magnesium to the identified subject. 8. The method of claim 1 , wherein the biological sample includes blood leukocyte DNA. 9. The method of claim 1 , and further comprising identifying the subject as being in need of magnesium supplementation when methylation is found at the CpG sites comprising: cg00430271, cg11840205, and cg25731074. 10. The method of claim 9 , and further comprising administering an effective amount of magnesium to the identified subject. 11. The method of claim 1 , and further comprising identifying the subject as being in need of magnesium supplementation when methylation is found at the CpG sites comprising: cg00430271, cg04386563, cg11840205, and cg25731074. 12. The method of claim 11 , and further comprising administering an effective amount of magnesium to the identified subject. 13. The method of claim 1 , and further comprising determining Ca:Mg ratio of the diet of the subject, and selecting the effective amount of magnesium to decrease the Ca:Mg ratio.

Assignees

Inventors

Classifications

  • Methylation markers · CPC title

  • Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} · CPC title

  • ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations · CPC title

  • C12Q1/6883Primary

    for diseases caused by alterations of genetic material · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12391990B2 cover?
The presently-disclosed subject matter includes methods for detecting methylation biomarkers in a biological sample from a subject in need of assessment for magnesium deficiency status, methods of diagnosing magnesium deficiency, methods of diagnosing magnesium insufficiency, methods of treating magnesium deficiency, methods of diagnosing magnesium insufficiency, and methods of preventing or re…
Who is the assignee on this patent?
Univ Vanderbilt
What technology area does this patent fall under?
Primary CPC classification C12Q1/6883. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).